Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IGF-I R

IGF-I R

Brief Information

Name:Insulin-like growth factor I receptor
Target Synonym:IGF-I receptor,IGF1R,Insulin Like Growth Factor 1 Receptor,Insulin-Like Growth Factor 1 Receptor,Insulin-Like Growth Factor I Receptor,Soluble IGF1R Variant 1,Soluble IGF1R Variant 2,CD221 Antigen,CD221,IGFIR,JTK13,IGFR,Receptor, IGF Type 1,MGC18216
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:16
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

IGR-H82E3-SPR
Human_FcRn_Heterodimer_Protein_SPR

Biotinylated Human IGF-I R, His,Avitag (Cat. No. IGR-H82E3) immobilized on CM5 Chip can bind Human IGF-I, His Tag (Cat. No. IG1-H5245) with an affinity constant of 33.9 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

IGR-H5229-SPR
Human_FcRn_Heterodimer_Protein_SPR

Human IGF-I R, His Tag (Cat. No. IGR-H5229) immobilized on CM5 Chip can bind Biotinylated Human IGF-I, His,Avitag (Cat. No. IG1-H82Q6) with an affinity constant of 68 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Synonym Name

IGF1R,IGFR,JTK13,CD221,MGC142170,MGC142172,MGC18216

Background

The Insulin-like Growth Factor 1 Receptor (IGF1) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the α and β subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane αβ chain.The α chains are located extracellularly while the β subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
IGF-1 (Biogen/Pharmacia & Upjohn) Approved Biogen Inc, Pharmacia & Upjohn Igef Sweden Dwarfism null 1994-01-01 Dwarfism Details
Teprotumumab R-1507; RG-1507; RO-4858696; HZN-001 Approved Genmab, F. Hoffmann-La Roche Ltd Tepezza United States Graves Ophthalmopathy Horizon Therapeutics Ireland 2020-01-21 Graves Ophthalmopathy Details
Mecasermin (Ipsen) IGF-1; FK-780; MKN-031 Approved Ipsen Increlex EU Laron Syndrome Ipsen Pharma 2005-08-30 Failure to Thrive; Laron Syndrome Details
Mecasermin (Astellas/OrphanPacific) Approved Astellas Pharma Inc Somazon Japan Dwarfism; Diabetes Mellitus, Lipoatrophic; Growth hormone deficiency null 1994-10-05 Diabetes Mellitus, Lipoatrophic; Dwarfism; Growth hormone deficiency Details
Brigatinib AP-26113 Approved Ariad, Takeda Pharmaceutical Co Ltd Alunbrig Mainland China Carcinoma, Non-Small-Cell Lung Takeda (China) International Trading Co Ltd 2017-04-28 Solid tumours; Ependymoma; Carcinoma; Neurofibromatosis 2; Neoplasms; Myofibroma; Granuloma, Plasma Cell; Lung Neoplasms; Lymphoma, Large-Cell, Anaplastic; Brain metastases; Carcinoma, Non-Small-Cell Lung; Meningioma; Neurilemmoma; Neuroma, Acoustic Details
Ceritinib LDK-378; NVP-LDK378; NVP-LDK378-NX Approved Novartis Pharma Ag 赞可达, Zykadia Mainland China Carcinoma, Non-Small-Cell Lung Novartis Europharm Ltd 2014-04-29 Hepatic Insufficiency; Melanoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Brain metastases; Carcinoma, Squamous Cell; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Hematologic Neoplasms; Colorectal Neoplasms; Neuroblastoma; Cholangiocarcinoma; Thyroid Carcinoma, Anaplastic; Neoplasms; Adenocarcinoma of Lung; Pancreatic Neoplasms; Glioblastoma; Stomach Neoplasms Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
124I-CPD-1023-figitumumab 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 Phase 1 Clinical Fusion Pharma Neoplasms Details
Insulin-Like Growth Factor 1 (Wright State Physicians) Phase 1 Clinical Wright State Physicians Nasolabial fold wrinkles; Sunburn Details
Lonigutamab VB-421 Phase 1 Clinical Pierre Fabre Group Graves Ophthalmopathy Details
Picropodophyllin PPP; AXL-1717; NSC-36407 Phase 2 Clinical Axelar Ab Astrocytoma; Carcinoma, Non-Small-Cell Lung Details
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) Phase 1 Clinical Sidney Kimmel Cancer Center Glioma Details
CT-102 CT-102 Phase 2 Clinical Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences Liver Neoplasms; Carcinoma, Hepatocellular Details
VRDN-002 VRDN-002 Phase 1 Clinical Viridian Therapeutics Inc Graves Ophthalmopathy Details
PHP-1003 PHP-1003; PHP1003 Phase 1 Clinical Graves Ophthalmopathy Details
BVS-857 BVS-857 Novartis Pharma Ag Details
Conteltinib CT-707; SY-707 Phase 3 Clinical Shouyao Holding (Beijing) Co Ltd, Centaurus Biopharma Co Ltd Carcinoma, Non-Small-Cell Lung Details
VPI-2690B VPI-2690B University Of North Carolina At Chapel Hill Details
Figitumumab CP-751871 Pfizer Inc Details
XL-228 XL-228 Exelixis Inc Details
lonigutamab ugodotin W-0101 Pierre Fabre Group Details
KW-2450 KW-2450 Kyowa Hakko Kirin Co Ltd Details
BIIB-022 BIIB-022 Biogen Inc Details
Dalotuzumab h7C-10; MK-0646; F-50-035 Pierre Fabre Group Details
BMS-754807 BMS-754807 Bristol-Myers Squibb Company Details
VF-001 VF-001; VF-001-DP-HD; VF-001-DP-LD Factor Therapeutics Details
FPI-1434 [225Ac]-FPI-1434; FPX-01 Phase 2 Clinical Fusion Pharma Neoplasms Details
Ganitumab AMG-479 Phase 3 Clinical Amgen Inc Prostatic Neoplasms; Gastrointestinal Neoplasms; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Sarcoma, Ewing; Breast Neoplasms; Sarcoma; Solid tumours; Pancreatic Neoplasms; Colonic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Rectal Neoplasms; Carcinoid Tumor; Ovarian Neoplasms; Intestinal Neoplasms Details
Linsitinib OSI-906; ASP-7487; OSI-906AA Phase 3 Clinical Astellas Pharma Inc, National Cancer Institute Solid tumours; Ovarian Neoplasms; Liver Neoplasms; Head and Neck Neoplasms; Thyroid Diseases; Hashimoto Disease; Neoplasms; Adrenocortical Carcinoma; Multiple Myeloma; Graves Ophthalmopathy; Endocrine System Diseases; Sarcoma, Ewing; Colorectal Neoplasms; Eye Diseases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
VRDN-001 VRDN-001; ZB-001; AVE-1642 Phase 2 Clinical Viridian Therapeutics Inc Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms Details
Teprotumumab biosimilar(Innovent) IBI-311 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Graves Ophthalmopathy Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message